Blood test aids in predicting lung cancer mortality risk
A blood-based test developed by researchers at The University of Texas MD Anderson Cancer Center can predict an individual’s risk of dying from lung cancer when combined with a personalized risk model.
According to new data published today in the Journal of Clinical Oncology, a blood-based four-protein panel (4MP), when combined with a lung cancer risk model (PLCOm2012), can better identify those at high risk of dying...
Largest-ever atlas of normal breast cells brings unprecedented insights into mammary biology
A new study led by researchers at The University of Texas MD Anderson Cancer, University of California, Irvine and Baylor College of Medicine...
MD Anderson Research Highlights for June 27, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
New understanding of why kidney cancers become metastatic discovered by MD Anderson researchers
Researchers at The University of Texas MD Anderson Cancer have engineered a new model of aggressive renal cell carcinoma (RCC), highlighting molecular targets and genomic events that trigger chromosomal instability and drive metastatic progression.
The study, published today in Nature Cancer, demonstrates that the loss of a cluster of interferon receptor (IFNR) genes plays a pivotal role in allowing cancer cells to become tolerant...
MD Anderson and Ochsner Health announce partnership to create first fully integrated cancer program in Louisiana
The University of Texas MD Anderson Cancer Center and New Orleans-based Ochsner Health today announced a partnership to create Ochsner...
Mutant KRAS regulates Y chromosome gene in colorectal cancer, driving metastasis and inhibiting anti-tumor immunity
Researchers at The University of Texas MD Anderson Cancer Center have uncovered a gene on the Y chromosome that is upregulated in KRAS-mutated...
MD Anderson and Replay announce FDA clearance of IND application for first-in-class TCR NK cell therapy for sarcoma
The University of Texas MD Anderson Cancer Center and Replay today announced that the Food & Drug Administration (FDA) has issued...
Adagrasib effective for patients with KRAS G12C-mutant lung cancer and untreated brain metastases
Researchers from The University of Texas MD Anderson Cancer Center found the KRAS G12C inhibitor adagrasib showed promising activity suppressing...
Study brings new understanding of multiple myeloma evolution
A new study by researchers at The University of Texas MD Anderson Cancer Center highlights novel insights into the evolution of multiple myeloma...
MD Anderson Research Highlights for June 7, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
ASCO: Axi-cel significantly improves survival in patients with early relapsed or refractory large B-cell lymphoma
ABSTRACT: LBA107
CHICAGO – Patients with early relapsed or refractory large B-cell lymphoma had significantly improved overall survival...
ASCO: Targeted therapy achieves responses across multiple cancer types with FGFR alterations
ABSTRACTS: 3121, 4504, LBA4619
Three clinical trials led by researchers at The University of Texas MD Anderson Cancer Center demonstrated...
ASCO: HER2-targeted antibody drug conjugate shows strong anti-tumor activity and durable responses across multiple tumor types
ABSTRACT: LBA3000
In a new study of trastuzumab deruxtecan, a HER2-targeted antibody drug conjugate, researchers observed encouraging...
ASCO: Targeted therapy induces responses in HER2-amplified biliary tract cancer
ABSTRACT: 4008
HER2-targeted bispecific antibody zanidatamab demonstrated durable responses in patients with treatment-refractory HER2...